Brazil's SUS Incorporates Bezafibrate for Primary Biliary Cholangitis
The public health system adds a new treatment option for rare autoimmune liver conditions.
1Official Treatment Expansion
The Brazilian Ministry of Health officially incorporated bezafibrate into the Unified Health System, known as SUS. This decision was formalized through Portaria SCTIE/MS number 73, published on November 6, 2026. The measure aims to provide a new therapeutic alternative for patients diagnosed with primary biliary cholangitis, a chronic autoimmune liver disease.
2Implementation Timeline Set
Following the publication of the ordinance, technical departments within the Ministry of Health have a maximum deadline of 180 days to ensure the medication is available across the public network. The regulation became effective immediately upon its release in the Federal Official Gazette, signed by Secretary Fernanda De Negri for health innovation.
3Understanding the Condition
Primary biliary cholangitis is a rare, chronic autoimmune condition that specifically targets the liver. The immune system attacks small bile ducts, which are essential channels for transporting bile to the intestines. This damage leads to inflammation and the progressive destruction of these vital pathways, causing bile to accumulate within the liver organ.
4Pathology and Liver Damage
As bile accumulates, it causes significant injury to hepatic cells, eventually resulting in tissue scarring known as fibrosis. In advanced stages, this process can progress to cirrhosis and total liver failure. Early identification is critical, as the disease often remains asymptomatic for years before manifesting through persistent fatigue or intense skin itching.
5Patient Demographic Profile
The disease predominantly affects women, particularly those over the age of 40. While the condition currently lacks a definitive cure, medical interventions focus on slowing disease progression and mitigating long-term liver damage. By adding bezafibrate to the public formulary, the government aims to prevent severe complications and improve overall patient quality of life.
6Clinical Recommendation Process
The decision to include the drug followed a rigorous evaluation by Conitec, the National Commission for the Incorporation of Technologies in the Unified Health System. The full recommendation report detailing the clinical evidence and rationale for this inclusion is currently accessible to the public on the commission's official website for further review.
7Broader Public Health Impact
Incorporating specialized medications into a national public system like SUS represents a significant shift in managing rare diseases. By expanding therapeutic options, the government reduces the financial burden on patients who previously lacked access to specific treatments. This policy aligns with broader efforts to standardize care for autoimmune disorders across the country.
8Future Monitoring Requirements
Health authorities will now monitor the distribution and efficacy of bezafibrate within the public network over the coming months. Patients and healthcare providers are expected to track clinical outcomes to assess the long-term impact of this new therapy. The focus remains on ensuring consistent supply chains to support patients nationwide effectively.
Original article: Poder360 — Brazil's SUS Incorporates Bezafibrate for Primary Biliary Cholangitis